{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:46:22Z","timestamp":1790419582413,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12028-020-00977-5","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:12:21Z","timestamp":1589238741000},"page":"283-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review"],"prefix":"10.1007","volume":"33","author":[{"given":"David J.","family":"Gagnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Riker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Nocella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"977_CR1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","volume":"18","author":"GBD 2016 Stroke Collaborators","year":"2019","unstructured":"GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439\u201358.","journal-title":"Lancet Neurol"},{"key":"977_CR2","doi-asserted-by":"crossref","unstructured":"Vickrey BG, Brott TG, Koroshetz WJ; Stroke Research Priorities Meeting Steering Committee and the National Advisory Neurological Disorders and Stroke Council; National Institute of Neurological Disorders and Stroke. Research priority setting: a summary of the 2012 NINDS Stroke Planning Meeting Report. Stroke 2013;44:2338\u201342.","DOI":"10.1161\/STROKEAHA.113.001196"},{"key":"977_CR3","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/STR.0000000000000098","volume":"47","author":"CJ Winstein","year":"2016","unstructured":"Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2016;47:e98\u2013169.","journal-title":"Stroke"},{"key":"977_CR4","doi-asserted-by":"crossref","unstructured":"Martinsson L, H\u00e5rdemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev 2007;(1):CD002090.","DOI":"10.1002\/14651858.CD002090.pub2"},{"key":"977_CR5","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1001\/jamaneurol.2018.2338","volume":"75","author":"LB Goldstein","year":"2018","unstructured":"Goldstein LB, Lennihan L, Rabadi MJ, Good DC, Reding MJ, Dromerick AW, et al. Effect of dextroamphetamine on poststroke motor recovery: a randomized clinical trial. JAMA Neurol. 2018;75:1494\u2013501.","journal-title":"JAMA Neurol"},{"issue":"14","key":"977_CR6","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096\u20139.","journal-title":"Neurology"},{"issue":"4","key":"977_CR7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00002826-198908000-00003","volume":"12","author":"T Gualtieri","year":"1989","unstructured":"Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol. 1989;12(4):258\u201370.","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl","key":"977_CR8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/0303-8467(92)90006-O","volume":"94","author":"JC Stoof","year":"1992","unstructured":"Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-d-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg. 1992;94(Suppl):S4\u20136.","journal-title":"Clin Neurol Neurosurg"},{"key":"977_CR9","first-page":"383","volume":"19","author":"I Jibiki","year":"1993","unstructured":"Jibiki I, Morikawa K, Yamaguchi N. Beneficial effect of amantadine on symptoms of dementia in patients with cerebral infarctions. Acta Ther. 1993;19:383\u20137.","journal-title":"Acta Ther."},{"key":"977_CR10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.v67n0406","volume":"67","author":"JS Ballon","year":"2006","unstructured":"Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67:554\u201366.","journal-title":"J Clin Psychiatry"},{"key":"977_CR11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0987-7053(01)00282-9","volume":"31","author":"A Autret","year":"2001","unstructured":"Autret A, Lucas B, Mondon K, Hommet C, Corcia P, Saudeau D, et al. Sleep and brain lesions: a critical review of the literature and additional new cases. Neurophysiol Clin. 2001;31:356\u201375.","journal-title":"Neurophysiol Clin"},{"key":"977_CR12","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"977_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12874-018-0545-3","volume":"18","author":"C Cooper","year":"2018","unstructured":"Cooper C, Booth A, Varley-Campbell J, Britten N, Garside R. Defining the process to literature searching in systematic reviews: a literature review of guidance and supporting studies. BMC Med Res Methodol. 2018;18:85.","journal-title":"BMC Med Res Methodol"},{"key":"977_CR14","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"977_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"977_CR16","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 10 Feb 2020."},{"key":"977_CR17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(98)05805-X","volume":"353","author":"T Nakagawa","year":"1999","unstructured":"Nakagawa T, Wada H, Sekizawa K, Arai H, Sasaki H. Amantadine and pneumonia. Lancet. 1999;353:1157.","journal-title":"Lancet"},{"key":"977_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000335895","volume":"68","author":"ST Engelter","year":"2012","unstructured":"Engelter ST, Urscheler N, Baronti F, Vuadens P, Koch J, Frank M, et al. Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur Neurol. 2012;68:28\u201333.","journal-title":"Eur Neurol"},{"key":"977_CR19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/02699059409151025","volume":"8","author":"JL Nickels","year":"1994","unstructured":"Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994;8:709\u201318.","journal-title":"Brain Inj"},{"key":"977_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0167-4943(02)00116-4","volume":"8","author":"R Raffaele","year":"2002","unstructured":"Raffaele R, Nicoletti G, Vecchio I, Ruggieri M, Malaguarnera M, Rampello L, et al. Use of amantadine in the treatment of the neurobehavioral sequelae after brain injury in elderly patients. Arch Gerontol Geriatr Suppl. 2002;8:309\u201312.","journal-title":"Arch Gerontol Geriatr Suppl"},{"key":"977_CR21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1310\/2403-B0CY-1UDN-4B6D","volume":"12","author":"RD Zorowitz","year":"2005","unstructured":"Zorowitz RD, Smout RJ, Gassaway JA, Horn SD. Neurostimulant medication usage during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). Top Stroke Rehabil. 2005;12:28\u201336.","journal-title":"Top Stroke Rehabil"},{"key":"977_CR22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/PHM.0b013e31811473b3","volume":"86","author":"AM Barrett","year":"2007","unstructured":"Barrett AM, Eslinger PJ. Amantadine for adynamic speech: possible benefit for aphasia? Am J Phys Med Rehabil. 2007;86:605\u201312.","journal-title":"Am J Phys Med Rehabil"},{"key":"977_CR23","first-page":"553","volume":"17","author":"A Pokryszko-Dragan","year":"2008","unstructured":"Pokryszko-Dragan A, S\u0142otwi\u0144ski K, Budrewicz SP, Podemski R, Zagrajek M, Bili\u0144ska M. Attention level and event-related evoked potentials in patients with cerebrovascular disease treated with amantadine sulfate - a pilot study. Adv Clin Exp Med. 2008;17:553\u20138.","journal-title":"Adv Clin Exp Med"},{"key":"977_CR24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/02699050902970745","volume":"23","author":"S Al-Adawi","year":"2009","unstructured":"Al-Adawi S, Hoaglin H, Vesali F, Dorvlo AS, Burke DT. Effect of amantadine on the sleep-wake cycle of an inpatient with brain injury. Brain Inj. 2009;23:559\u201365.","journal-title":"Brain Inj"},{"key":"977_CR25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00701-014-2077-x","volume":"156","author":"JM Avecillas-Chas\u00edn","year":"2014","unstructured":"Avecillas-Chas\u00edn JM, Barcia JA. Effect of amantadine in minimally conscious state of non-traumatic etiology. Acta Neurochir (Wien). 2014;156:1375\u20137.","journal-title":"Acta Neurochir (Wien)"},{"key":"977_CR26","doi-asserted-by":"crossref","unstructured":"Lehnerer SM, Scheibe F, Buchert R, Kliesch S, Meisel A. Awakening with amantadine from a persistent vegetative state after subarachnoid haemorrhage. BMJ Case Rep 2017; pii: bcr-2017-220305.","DOI":"10.1136\/bcr-2017-220305"},{"issue":"2","key":"977_CR27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5152\/TJAR.2018.20280","volume":"46","author":"EF Ak\u00e7\u0131l","year":"2018","unstructured":"Ak\u00e7\u0131l EF, Dilmen \u00d6K, Vehid H, Tunal\u0131 Y. Can amantadine ameliorate neurocognitive functions after subarachnoid haemorrhage? A preliminary study. Turk J Anaesthesiol Reanim. 2018;46(2):100\u20137.","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"977_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1300\/J092v08n02_06","volume":"8","author":"JW Cochran","year":"2001","unstructured":"Cochran JW. Effect of modafinil on fatigue associated with neurological illnesses. J. Chronic Fatigue Syndr. 2001;8:65\u201370.","journal-title":"J. Chronic Fatigue Syndr"},{"key":"977_CR29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1525-5050(03)00058-1","volume":"4","author":"BW Smith","year":"2003","unstructured":"Smith BW. Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke. Epilepsy Behav. 2003;4:352\u20133.","journal-title":"Epilepsy Behav"},{"key":"977_CR30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1176\/appi.psy.45.1.80","volume":"45","author":"SG Sugden","year":"2004","unstructured":"Sugden SG, Bourgeois JA. Modafinil monotherapy in poststroke depression. Psychosomatics. 2004;45:80\u20131.","journal-title":"Psychosomatics"},{"key":"977_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000232927","volume":"62","author":"A Brioschi","year":"2009","unstructured":"Brioschi A, Gramigna S, Werth E, Staub F, Ruffieux C, Bassetti C, et al. Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. Eur Neurol. 2009;62:243\u20139.","journal-title":"Eur Neurol"},{"key":"977_CR32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000322134","volume":"64","author":"ST Engelter","year":"2010","unstructured":"Engelter ST, Frank M, Lyrer PA, Conzelmann M. Safety of pharmacological augmentation of stroke rehabilitation. Eur Neurol. 2010;64:325\u201330.","journal-title":"Eur Neurol"},{"key":"977_CR33","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/j.1468-1331.2012.03835.x","volume":"19","author":"I Zavalko","year":"2012","unstructured":"Zavalko I, Bassetti CL, Cianfoni A, Carugati J, Fulda S, Manconi M. Hypersomnia due to bilateral thalamic lesions: unexpected response to modafinil. Eur J Neurol. 2012;19:e125\u20136.","journal-title":"Eur J Neurol"},{"key":"977_CR34","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1161\/STROKEAHA.115.010860","volume":"46","author":"MB Poulsen","year":"2015","unstructured":"Poulsen MB, Damgaard B, Zerahn B, Overgaard K, Rasmussen RS. Modafinil may alleviate poststroke fatigue: a randomized, placebo-controlled, double-blinded trial. Stroke. 2015;46:3470\u20137.","journal-title":"Stroke"},{"key":"977_CR35","doi-asserted-by":"crossref","first-page":"e6103","DOI":"10.1097\/MD.0000000000006103","volume":"96","author":"SH Jang","year":"2017","unstructured":"Jang SH, Seo JP. Restoration of the ascending reticular activating system compressed by hematoma in a stroke patient. Medicine (Baltimore). 2017;96:e6103.","journal-title":"Medicine (Baltimore)"},{"key":"977_CR36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/STROKEAHA.116.016293","volume":"48","author":"A Bivard","year":"2017","unstructured":"Bivard A, Lillicrap T, Krishnamurthy V, Holliday E, Attia J, Pagram H, et al. MIDAS (modafinil in debilitating fatigue after stroke): a randomized, double-blind, placebo-controlled, cross-over trial. Stroke. 2017;48:1293\u20138.","journal-title":"Stroke"},{"key":"977_CR37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fneur.2018.00269","volume":"9","author":"TP Lillicrap","year":"2018","unstructured":"Lillicrap TP, Levi CR, Holliday E, Parsons MW, Bivard A. Short- and long-term efficacy of modafinil at improving quality of life in stroke survivors: a post hoc sub study of the modafinil in debilitating fatigue after stroke trial. Front Neurol. 2018;9:269.","journal-title":"Front Neurol"},{"key":"977_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/02699058809150901","volume":"2","author":"MC Chandler","year":"1988","unstructured":"Chandler MC, Barnhill JL, Gualtieri CT. Amantadine for the agitated head-injury patient. Brain Inj. 1988;2:309\u201311.","journal-title":"Brain Inj"},{"key":"977_CR39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/026990599121061","volume":"13","author":"WN Schneider","year":"1999","unstructured":"Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13:863\u201372.","journal-title":"Brain Inj"},{"key":"977_CR40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00001199-200208000-00004","volume":"17","author":"JM Meythaler","year":"2002","unstructured":"Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002;17:300\u201313.","journal-title":"J Head Trauma Rehabil"},{"key":"977_CR41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1102609","volume":"366","author":"JT Giacino","year":"2012","unstructured":"Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819\u201326.","journal-title":"N Engl J Med"},{"key":"977_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jnnp.2007.124099","volume":"79","author":"C Schnakers","year":"2008","unstructured":"Schnakers C, Hustinx R, Vandewalle G, Majerus S, Moonen G, Boly M, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry. 2008;79:225\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"977_CR43","first-page":"4167","volume":"20","author":"O Gosseries","year":"2014","unstructured":"Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014;20:4167\u201384.","journal-title":"Curr Pharm Des"},{"key":"977_CR44","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1161\/STR.0000000000000132","volume":"48","author":"JL Hinkle","year":"2017","unstructured":"Hinkle JL, Becker KJ, Kim JS, Choi-Kwon S, Saban KL, McNair N, et al. Poststroke fatigue: emerging evidence and approaches to management: a scientific statement for healthcare professionals from the American Heart Association. Stroke. 2017;48:e159\u201370.","journal-title":"Stroke"},{"key":"977_CR45","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/02699052.2019.1644376","volume":"33","author":"J Annen","year":"2019","unstructured":"Annen J, Filippini MM, Bonin E, Cassol H, Aubinet C, Carri\u00e8re M, et al. Diagnostic accuracy of the CRS-R index in patients with disorders of consciousness. Brain Inj. 2019;33:1409\u201312.","journal-title":"Brain Inj"},{"key":"977_CR46","doi-asserted-by":"publisher","unstructured":"Almojuela A, Hasen M, Zeiler FA. The Full Outline of UnResponsiveness (FOUR) Score and its use in outcome prediction: a scoping systematic review of the adult literature. Neurocrit Care 2018 https:\/\/doi.org\/10.1007\/s12028-018-0630-9. [Epub ahead of print].","DOI":"10.1007\/s12028-018-0630-9"},{"key":"977_CR47","first-page":"94","volume":"68","author":"WD Gouvier","year":"1987","unstructured":"Gouvier WD, Blanton PD, LaPorte KK, Nepomuceno C. Reliability and validity of the Disability Rating Scale and the Levels of Cognitive Functioning Scale in monitoring recovery from severe head injury. Arch Phys Med Rehabil. 1987;68:94\u20137.","journal-title":"Arch Phys Med Rehabil"},{"key":"977_CR48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.seizure.2017.06.022","volume":"50","author":"AL Turner","year":"2017","unstructured":"Turner AL, Perry MS. Outside the box: medications worth considering when traditional antiepileptic drugs have failed. Seizure. 2017;50:173\u201385.","journal-title":"Seizure"},{"key":"977_CR49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.resuscitation.2017.12.002","volume":"123","author":"A Steinberg","year":"2018","unstructured":"Steinberg A, Rittenberger JC, Baldwin M, Faro J, Urban A, Zaher N, et al. Neurostimulant use is associated with improved survival in comatose patients after cardiac arrest regardless of electroencephalographic substrate. Resuscitation. 2018;123:38\u201342.","journal-title":"Resuscitation"},{"key":"977_CR50","first-page":"e13295","volume":"73","author":"RL Pacheco","year":"2019","unstructured":"Pacheco RL, Latorraca COC, da Silva LDGM, Ferreira DBGM, Fernandes CAA, Hosni ND, et al. Modafinil for poststroke patients: a systematic review. Int J Clin Pract. 2019;73:e13295.","journal-title":"Int J Clin Pract"},{"key":"977_CR51","unstructured":"Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. https:\/\/effectivehealthcare.ahrq.gov\/products\/cer-methods-guide. Accessed 2 Oct 2020."},{"key":"977_CR52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imj.12073","volume":"43","author":"S Geffen","year":"2013","unstructured":"Geffen S, Shum K, Tan HM. Novel use of modafinal to treat severe physical and cognitive impairment post-stroke. Intern Med J. 2013;43:338.","journal-title":"Intern Med J"},{"key":"977_CR53","unstructured":"Benefits of Amantadine in Patients with Coma State. Accessed on June 1, 2019 at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443037?cond=amantadine&rank=1."},{"key":"977_CR54","unstructured":"Modafinil In Debilitating Fatigue After Stroke 2 (MIDAS 2). Accessed on June 1, 2019 at https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=374808."}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-020-00977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-020-00977-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-020-00977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:18:42Z","timestamp":1620775122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-020-00977-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s12028-020-00977-5","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"12 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We adhered to ethical guidelines. The Institutional Review Board at Maine Medical Center did not require approval for this systematic review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No financial support was provided for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Disclosures"}}]}}